Elizabeth Kiracofe, MD, FAAD

Looking to the future of atopic dermatitis treatment, Drs Kiracofe and Murase offer concluding remarks on current unmet needs, the benefits of treatment guidelines, and the importance of treating itch in patients who are or may become pregnant.

Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, have a comprehensive discussion on treatment safety considerations for patients with atopic dermatitis who are breastfeeding.

Experts on atopic dermatitis weigh the risks and rewards of systemic treatments for pregnant patients and provide clinical insights on monitoring for adverse effects associated with dupilumab.

Drs Kiracofe and Murase provide clinical insights on treatment escalation practices for patients with atopic dermatitis who are pregnant.

Focusing on pregnant patients with atopic dermatitis who are treatment naïve, Elizabeth Kiracofe, MD, FAAD, and Jenny Murase, MD, discuss best practices for informing patients on the available treatment options for this condition.

Jenny Murase, MD, provides a brief overview of the Fc receptor and the role of transcription binding in atopic dermatitis.

Dermatologists provide clinical insights on how they discuss atopic dermatitis treatment options, considerations, and safety concerns with patients who are pregnant or of childbearing age.

Jenny Murase, MD, describes how rising estrogen levels cause a shift in immune response from Th1 to Th2, causing potential atopic dermatitis exacerbations for patients who are pregnant.

Experts on atopic dermatitis discuss the importance of open dialogue with patients who are pregnant or of childbearing potential regarding the safety concerns associated with treatments for this condition.

Dr. Elizabeth Kiracofe, MD, FAAD, and Dr. Jenny Murase, MD, introduce a discussion on the undertreatment of patients with atopic dermatitis, particularly focusing on pregnant individuals and those of childbearing age.

Dr. Elizabeth Kiracofe discusses a case of unstable vitiligo in a 35-year-old male, addressing the impact of an outdoor lifestyle on treatment, the efficacy of topical ruxolitinib, and its utility in difficult-to-repigment areas.

Elizabeth Kiracofe, MD, FAAD presents a case of a 42-year-old woman with facial vitiligo, emphasizing the need for personalized treatment plans. She shares insights on patient follow-up, monitoring practices, and physician preferences in treatment modalities based on the vehicle.